Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Rossebø AB, et al. Among authors: holme i. N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2. N Engl J Med. 2008. PMID: 18765433 Free article. Clinical Trial.
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R. Gerdts E, et al. Among authors: holme i. Am J Cardiol. 2010 Dec 1;106(11):1634-9. doi: 10.1016/j.amjcard.2010.07.042. Epub 2010 Oct 14. Am J Cardiol. 2010. PMID: 21094366 Clinical Trial.
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Rossebø AB, et al. Among authors: holme i. Am J Cardiol. 2007 Apr 1;99(7):970-3. doi: 10.1016/j.amjcard.2006.10.064. Epub 2007 Feb 15. Am J Cardiol. 2007. PMID: 17398194 Clinical Trial.
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebø A, Pedersen TR, Skjærpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Bärwolf C. Jander N, et al. Among authors: holme i. Circulation. 2011 Mar 1;123(8):887-95. doi: 10.1161/CIRCULATIONAHA.110.983510. Epub 2011 Feb 14. Circulation. 2011. PMID: 21321152 Clinical Trial.
Adjusting parameters of aortic valve stenosis severity by body size.
Minners J, Gohlke-Baerwolf C, Kaufmann BA, Bahlmann E, Gerdts E, Boman K, Chambers JB, Nienaber CA, Willenheimer R, Wachtell K, Holme I, Pedersen TR, Neumann FJ, Jander N. Minners J, et al. Among authors: holme i. Heart. 2014 Jul;100(13):1024-30. doi: 10.1136/heartjnl-2013-305225. Epub 2014 Apr 29. Heart. 2014. PMID: 24780909
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. Holme I, et al. Ann Med. 2008;40(6):456-64. doi: 10.1080/07853890801964955. Ann Med. 2008. PMID: 19160529 Free article. Clinical Trial.
367 results